Patents Assigned to HEBEI SENLANG BIOTECHNOLOGY CO., LTD
  • Publication number: 20210154231
    Abstract: A method for producing ?? T cells modified by a chimeric antigen receptor, comprising: transfecting K562 cells with shFPPS targeted to FPP synthase by means of a lentiviral vector, such that the expression of FPPS in the K562 cells is lowered and a K562-shFPPS cell line with reduced FPPS expression is constructed; adding the K562-shFPPS cell line into a ?? T cell culture system for co-culturing with the ?? T cells, wherein it is found that the K562-shFPPS cell line can facilitate in vitro differentiation and proliferation of the ?? T cells; and adding a CAR-expressing lentiviral vector to the ?? T cell culture system comprising the cell line for co-culturing, wherein it is found that the K562-shFPPS cell line can further effectively improve the transfection rate of CAR genes. The provided solution effectively overcomes the technical challenge of the large-scale production of CAR-?? T cells, and has a good application prospect.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 27, 2021
    Applicant: HEBEI SENLANG BIOTECHNOLOGY CO., LTD
    Inventors: Jianqiang LI, Qinglong WANG, Lin WANG